About our research group/lab
About our research group
Why was this group formed?
cancer is the most common malignancy among Western populations. Skin cancer patients may suffer from multiple skin tumors, risk of recurrence and a decreased health-related quality of life. Our aim is to improve patient care by providing personalized health care (e.g. prediction models to identify patients at high risk for (multiple) skin cancers or personalized patient information), by optimizing surgical techniques (e.g. Raman spectrometry during Mohs Micrographic Surgery) or by increasing awareness and opportunities for improved patient care among health care policy makers (e.g. describe skin cancer epidemiology).
What is the overall aim?
We aim to increase awareness of the rapid skin cancer increases among health policy makers and to emphasize the urgency for prevention strategies and management of skin cancer patients. Skin cancer is the 5th most expensive cancer, mainly due to the large incidence rates. Skin cancer has an impact on the quality of life of a large number of patients. Therefore, another aim or our research is to improve the quality of patient care in an cost-effective way.
What type of research do we focus on in this group
- Skin cancer epidemiology, using data from the Netherlands Cancer Registry (NCR), Pathologisch Anatomisch Landelijk Geautomatiseerd Archief (PALGA) and Rotterdam Study
- Quality of life research, such as the development of the Basal and Squamous Quality of Life questionnaire ( BaSQoL)
- Qualitative research: interviews and focusgroups to gain in-depth
- information on behavior, considerations and needs of patients and physicians.
- Clinical research: clinical registries and application of innovative techniques to improve skin cancer care e.g. Raman spectroscopy, mobile apps, imaging.)
- Skin cancer genetics: genome wide association studies in the Rotterdam study are used to study genetics of skin cancer.
Prediction models for (multiple) skin cancers
Greveling K1, Wakkee M1, Nijsten T1, van den Bos RR1, Hollestein LM2.Epidemiology of Lentigo Maligna and Lentigo Maligna Melanoma in the Netherlands, 1989-2013.J Invest Dermatol. 2016 Oct;136(10):1955-1960. doi: 10.1016/j.jid.2016.06.014. Epub 2016 Jun 24.
Pardo LM1, Li WQ2,3, Hwang SJ4,5, Verkouteren JA1, Hofman A6,7, Uitterlinden AG8, Kraft P9,10, Turman C9, Han J10,11,12, Cho E2,3,10, Murabito JM4,13, Levy D4,5, Qureshi AA2,3,10, Nijsten T1.Genome-Wide Association Studies of Multiple Keratinocyte Cancers.PLoS One. 2017 Jan 12;12(1):e0169873. doi: 10.1371/journal.pone.0169873. eCollection 2017.
Verkouteren JAC1, Smedinga H2, Steyerberg EW2, Hofman A3, Nijsten T4.Predicting the Risk of a Second Basal Cell Carcinoma.J Invest Dermatol. 2015 Nov;135(11):2649-2656. doi: 10.1038/jid.2015.244. Epub 2015 Mar 3.
Boitor R1, Kong K1, Shipp D1, Varma S2, Koloydenko A3, Kulkarni K4, Elsheikh S4, Schut TB5,6, Caspers P5,6, Puppels G5,6, van der Wolf M6, Sokolova E6, Nijsten TEC5, Salence B7, Williams H8, Notingher I1.Automated multimodal spectral histopathology for quantitativediagnosis of residual tumour during basal cell carcinoma surgery.Biomed Opt Express. 2017 Nov 22;8(12):5749-5766. doi: 10.1364/BOE.8.005749. eCollection 2017 Dec 1.
van Lee CB1, Roorda BM2, Wakkee M1, Voorham Q3, Mooyaart AL4, de Vijlder HC5, Nijsten T1, van den Bos RR1.Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study.Br J Dermatol. 2018 Sep 10. doi: 10.1111/bjd.17188. [Epub ahead of print]
Waalboer-Spuij R1, Hollestein LM, Timman R, van de Poll-Franse LV, Nijsten TE.Development and Validation of the Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) Questionnaire.Acta Derm Venereol. 2018 Feb 7;98(2):234-239. doi: 10.2340/00015555-2806.
Collaborations within Erasmus MC
Dept. Epidemiology - Rotterdam Study
Dept. Public Health
Dept. of Pathology
Dept. participating in the multidisciplinary skin cancer team
Collaborations outsite Erasmus MC
Netherlands Cancer Registry, facilitated by IKNL (www.cijfersoverkanker.nl)
University of Nottingham, Raman group, http://www.biophotonics-nottingham-nanoscience.net/home
Funding & Grants
Erasmus MC Doelmatigheidsonderzoek